Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:56:12.910Z.
Calculation as of: 2026-10-06T14:56:12.910Z.
Quote observation: 2026-10-06T14:55:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5c882cca81b2c0fe2c09916b57b0a50c93804d18514abf2397940823ad07c5bd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
CAMP4 Therapeutics Corporation
Market Cap
$240.34M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.07M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$238.91M
Operating Cash Flow Yield
17.39%
TTM Avg
15.21%
3Y Avg
15.21%
5Y Avg
15.21%
Market Cap
$236.81M
Operating Cash Flow Yield
7.55%
TTM Avg
8.86%
3Y Avg
9.94%
5Y Avg
8.17%
Market Cap
$244.00M
Operating Cash Flow Yield
N/A
TTM Avg
1.55%
3Y Avg
1.55%
5Y Avg
2.54%
Market Cap
$238.40M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$234.93M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CAMP4 Therapeutics Corporation (CAMP) | $240.34M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $238.61M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.07M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $238.91M | 17.39% | 15.21% | 15.21% | 15.21% |
| High Tide Inc. (HITI)vs › | $236.81M | 7.55% | 8.86% | 9.94% | 8.17% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $244.00M | N/A | 1.55% | 1.55% | 2.54% |
| Invivyd, Inc. (IVVD)vs › | $244.02M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $238.40M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $234.93M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $232.69M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
